Changes in matrix metalloproteinases and their inhibitors in kidney transplant recipients

Experimental and Clinical Transplantation

Volumn 10, Issue 4, 2012, Pages 332-343

  Ahmed, Aimun K ^a   Meguid El Nahas, A ^b   Johnson, Timothy S ^b  

^a ROYAL PRESTON HOSPITAL   (United Kingdom)

^b NORTHERN GENERAL HOSPITAL   (United Kingdom)

Author keywords

Kidney scarring; Kidney transplant; Matrix metalloproteinases; Tissue inhibitors of matrix metalloproteinases

Indexed keywords

AZATHIOPRINE; COLLAGEN TYPE 1; CYCLOSPORIN; GELATIN; GELATINASE A; GELATINASE B; INTERSTITIAL COLLAGENASE; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE INHIBITOR; METHYLPREDNISOLONE; PREDNISOLONE; STROMELYSIN;

ACUTE GRAFT REJECTION; ARTICLE; CHRONIC ALLOGRAFT NEPHROPATHY; ENZYME ACTIVITY; EXTRACELLULAR MATRIX; GRAFT FAILURE; GRAFT RECIPIENT; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTERSTITIAL NEPHRITIS; KIDNEY BIOPSY; KIDNEY SCAR; KIDNEY TRANSPLANTATION; RETROSPECTIVE STUDY; ZYMOGRAPHY;

ACUTE DISEASE; ADULT; BIOPSY; CHRONIC DISEASE; DOWN-REGULATION; ENGLAND; FEMALE; FIBROSIS; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNOHISTOCHEMISTRY; KIDNEY; KIDNEY DISEASES; KIDNEY TRANSPLANTATION; LINEAR MODELS; MALE; MATRIX METALLOPROTEINASE 1; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 3; MATRIX METALLOPROTEINASE 9; MATRIX METALLOPROTEINASES; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TISSUE INHIBITOR OF METALLOPROTEINASE-2; TISSUE INHIBITOR OF METALLOPROTEINASE-3; TISSUE INHIBITOR OF METALLOPROTEINASES; TREATMENT OUTCOME; UP-REGULATION;

EID: 84865080227     PISSN: 13040855     EISSN: None     Source Type: Journal    
DOI: 10.6002/ect.2012.0013     Document Type: Article

References (39)

1. Wolfe RA, Ashby VB, Milford EL, et al. Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant. N Engl J Med. 1999;341(23):1725-1730.
2. Oniscu GC, Brown H, Forsythe JL. Impact of cadaveric renal transplantation on survival in patients listed for transplantation. J Am Soc Nephrol. 2005;16(6):1859-1865.
3. Riaño-Galán I, Málaga S, Rajmil L, et al. Quality of life of adolescents with end-stage renal disease and kidney transplant. Pediatr Nephrol. 2009;24(8):1561-1568.
4. Schnuelle P, Lorenz D, Trede M, Van Der Woude FJ. Impact of renal cadaveric transplantation on survival in end-stage renal failure: evidence for reduced mortality risk compared with hemodialysis during long-term follow-up. J Am Soc Nephrol. 1998;9(11):2135-2141.
5. Hariharan S, Stablein DE. Improvements in long-term renal transplant graft survival. Am J Transplant. 2005;5(3):630-631; author reply 632-633.
6. Hariharan S, Johnson CP, Bresnahan BA, Taranto SE, McIntosh MJ, Stablein D. Improved graft survival after renal transplantation in the United States, 1988 to 1996. N Engl J Med. 2000;342(9):605-612.
7. Jorga A, Johnston A. Novel therapies in transplantation. Expert Opin Investig Drugs. 2005;14(3):295-304.
8. Womer KL, Kaplan B. Recent developments in kidney transplantation--a critical assessment. Am J Transplant. 2009;9(6):1265-1271.
9. Wiland AM, Fink JC, Weir MR, et al. Should living-unrelated renal transplant recipients receive antibody induction? Results of a clinical experience trial. Transplantation. 2004;77(3):422-425.
10. Knoll G. Trends in kidney transplantation over the past decade. Drugs. 2008;68(suppl 1):3-10.
11. Jevnikar AM, Mannon RB. Late kidney allograft loss: what we know about it, and what we can do about it. Clin J Am Soc Nephrol. 2008;3(suppl 2):S56-S67.
12. Najafian B, Kasiske BL. Chronic allograft nephropathy. Curr Opin Nephrol Hypertens. 2008;17(2):149-155.
13. Vongwiwatana A, Tasanarong A, Hidalgo LG, Halloran PF. The role of B cells and alloantibody in the host response to human organ allografts. Immunol Rev. 2003;196(1):197-218.
14. Yates PJ, Nicholson ML. The aetiology and pathogenesis of chronic allograft nephropathy. Transpl Immunol. 2006;16(3-4):148-157.
15. Lenz O, Elliot SJ, Stetler-Stevenson WG. Matrix metalloproteinases in renal development and disease. J Am Soc Nephrol. 2000;11(3):574-581.
16. Liu Y. Renal fibrosis: new insights into the pathogenesis and therapeutics. Kidney Int. 2006;69(2):213-217.
17. Engelmyer E, van Goor H, Edwards DR, Diamond JR. Differential mRNA expression of renal cortical tissue inhibitor of metalloproteinase-1,-2, and-3 in experimental hydronephrosis. J Am Soc Nephrol. 1995;5(9):1675-1683.
18. Lutz J, Yao Y, Song E, et al. Inhibition of matrix metalloproteinases during chronic allograft nephropathy in rats. Transplantation. 2005;79(6):655-661.
19. Rodrigo E, López-Hoyos M, Escallada R, et al. Circulating levels of matrix metalloproteinases MMP-3 and MMP-2 in renal transplant recipients with chronic transplant nephropathy. Nephrol Dial Transplant. 2000;15(12):2041-2045.
20. Rodrigo E, López Hoyos M, Escallada R, et al. Changes in serum concentrations of matrix metalloproteinases in kidney transplantation. Transplant Proc. 2000;32(3):517-518.
21. Ahmed AK, Haylor JL, El Nahas AM, Johnson TS. Localization of matrix metalloproteinases and their inhibitors in experimental progressive kidney scarring. Kidney Int. 2007;71(8):755-763.
22. Schwartz SM, Gordon D, Mosca RS, Bove EL, Heidelberger KP, Kulik TJ. Collagen content in normal, pressure, and pressure-volume overloaded developing human hearts. Am J Cardiol. 1996;77(9):734-738.
23. McQuaid S, McConnell R, McMahon J, Herron B. Microwave antigen retrieval for immunocytochemistry on formalin-fixed, paraffin-embedded post-mortem CNS tissue. J Pathol. 1995;176(2):207-216.
24. Schnaper HW, Kopp JB, Poncelet AC, et al. Increased expression of extracellular matrix proteins and decreased expression of matrix proteases after serial passage of glomerular mesangial cells. J Cell Sci. 1996;109(Pt 10):2521-2528.
25. González-Avila G, Iturria C, Vadillo-Ortega F, Ovalle C, Montaño M. Changes in matrix metalloproteinases during the evolution of interstitial renal fibrosis in a rat experimental model. Pathobiology. 1998;66(5):196-204.
26. Johnson TS, Haylor JL, Thomas GL, Fisher M, El Nahas AM. Matrix metalloproteinases and their inhibitions in experimental renal scarring. Exp Nephrol. 2002;10(3):182-195.
27. Suzuki D, Miyazaki M, Jinde K, et al. In situ hybridization studies of matrix metalloproteinase-3, tissue inhibitor of metalloproteinase-1 and type IV collagen in diabetic nephropathy. Kidney Int. 1997;52(1):111-119.
28. Del Prete D, Anglani F, Forino M, et al. Down-regulation of glomerular matrix metalloproteinase-2 gene in human NIDDM. Diabetologia. 1997;40(12):1449-1454.
29. Miyazaki M, Nishino T, Abe K, Furusu A, Koji T, Kohno S. Contrib Nephrol. 2003;139:141-155.
30. Norman JT, Gatti L, Wilson PD, Lewis M. Matrix metalloproteinases and tissue inhibitor of matrix metalloproteinases expression by tubular epithelia and interstitial fibroblasts in the normal kidney and in fibrosis. Exp Nephrol. 1995;3(2):88-89.
31. Sanders JS, van Goor H, Hanemaaijer R, Kallenberg CG, Stegeman CA. Renal expression of matrix metalloproteinases in human ANCAassociated glomerulonephritis. Nephrol Dial Transplant. 2004;19(6):1412-1419.
32. Nicholson ML, Waller JR, Bicknell GR. Renal transplant fibrosis correlates with intragraft expression of tissue inhibitor of metalloproteinase messenger RNA. Br J Surg. 2002;89(7):933-937.
33. Brook NR, White SA, Waller JR, Bicknell GR, Nicholson ML. Fibrosisassociated gene expression in renal transplant glomeruli after acute renal allograft rejection. Br J Surg. 2003;90(8):1009-1014.
34. Miyata Y, Kanda S, Nomata K, Hayashida Y, Kanetake H. Expression of metalloproteinase-2, metalloproteinase-9, and tissue inhibitor of metalloproteinase-1 in transitional cell carcinoma of upper urinary tract: correlation with tumor stage and survival. Urology. 2004;63(3):602-608.
35. Chromek M, Tullus K, Hertting O, et al. Matrix metalloproteinase-9 and tissue inhibitor of metalloproteinases-1 in acute pyelonephritis and renal scarring. Pediatr Res. 2003;53(4):698-705.
36. Nazneen A, Razzaque MS, Liu D, Taguchi T. Possible role of Ets-1 and MMP-1 in matrix remodeling in experimental cisplatin nephropathy. Med Electron Microsc. 2002;35(4):242-247.
37. Kallakury BV, Karikehalli S, Haholu A, Sheehan CE, Azumi N, Ross JS. Increased expression of matrix metalloproteinases 2 and 9 and tissue inhibitors of metalloproteinases 1 and 2 correlate with poor prognostic variables in renal cell carcinoma. Clin Cancer Res. 2001;7(10):3113-3119.
38. Noë V, Fingleton B, Jacobs K, et al. Release of an invasion promoter E-cadherin fragment by matrilysin and stromelysin-1. J Cell Sci. 2001;114(Pt 1):111-118.
39. Malemud CJ. Matrix metalloproteinases: role in skeletal development and growth plate disorders. Front Biosci. 2006;11:1702-1715.